{"schema_version":"secwatch.filing_event.v1","accession":"0001520138-22-000390","form_type":"8-K","ticker":"BIVI","cik":"0001580149","company_name":"BIOVIE INC.","filed_at":"2022-09-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.241380+00:00","generated_at":"2026-06-23T14:10:02.478686+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BioVie NE3107 Phase 2 trial: 82% of mild AD patients improved ADAS-Cog12 by 2.6 pts (p=0.0046); Phase 3 50% enrolled","bullets":["23-patient open-label Phase 2: 82% of mild AD patients (MMSE>=20) showed mean 2.6-point ADAS-Cog12 improvement (p=0.0046); no drug-related adverse events.","Reduction in TNF alpha significantly correlated with cognitive improvement (R=0.70, p=0.0077).","Phase 3 AD trial (NCT04669028) 50% enrolled of 316 target; DSMB review later in 2022 may adjust sample size up to 400; topline expected mid-2023.","Phase 2 Parkinson's trial (NCT05083260) enrolling 40 patients; data readout by end of 2022; no drug-related AEs seen yet.","Phase 2b BIV201 trial in refractory ascites enrollment delayed by COVID; data readout now anticipated by mid-2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001520138-22-000390","json":"https://secwatch.observer/filing/0001520138-22-000390.json","markdown":"https://secwatch.observer/filing/0001520138-22-000390.md","text":"https://secwatch.observer/filing/0001520138-22-000390.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1580149/000152013822000390/0001520138-22-000390-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1580149/000152013822000390/bivi-20220907_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T14:10:02.478686+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}